Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease

A Phaseiia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease.

The study is to evaluate the safety, tolerability and whether there is an immune system response to multiple doses of ACC-001 with or without the use of a substance that may increase the response to the drug.

Inclusion Criteria:

• Diagnosis of mild to moderate Alzheimer's Disease
• Mini Mental Status Exam (MMSE) of 16-26

Exclusion Criteria:

• Significant Neurological Disease
• Major Psychiatric Disorder
• Clinically significant systemic illness